Journal Article

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma

Grimaldi, A. M., Arcella, A., Tatangelo, F., Cicala, D., Ascierto, P. A., von Arx, C., De Divitiis, C., Romano, G. M., Tafuto, S., Simeone, E., Iaffaioli, R. V.

2016

Overview

Neuroendocrine Neoplasms (NEN) are a group of heterogeneous malignancies derived from neuroendocrine cell compartment, with different roles in both endocrine and nervous system. Most NETs have gastroentero-pancreatic (GEP) origin, arising in the foregut, midgut, or hindgut. The 2010 WHO classification divides GEP-NETs into two main subgroups, neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC), according with Ki-67 levels. NET are tumors with low (<20 %) Ki-67 value, and NECs, including small cell lung carcinomas and Merkel Cell carcinomas, are all NETs with high Ki-67 levels (>20 %–G3). Poorly differentiated neuroendocrine carcinomas (NEC) are usually treated with cisplatin-based chemotherapy regimens. Here we present a case of a patient with pancreatic NEC progressing after cisplatin and etoposide, treated with temozolomide as palliative, second line treatment. According with the poor Performance Status (PS = 2) and to reduce the toxicity of the treatment was chosen an intermittent dosing regimen of metronomic temozolomide (75 mg/m 2 /day—one-week-on/on-week-off). MGMT resulted methylated. On July 2014 the patient started the treatment. On August 2014 the patient obtained a significant clinical benefit (PS = 0) and the total body CT scan performed on October 2014 showed a RECIST partial response on all the sites of disease. No drug-related side effects were reported by the patient. After 18 months of therapy the treatment continues without significant toxicity, and with further remission of the metastases. Treatment with metronomic “one-week-on/on-week-off” Temozolomide can be considered a good treatment option in patients with poor performance status, affected by pNEC with MGMT methylation.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V
• Subject: Administration, Metronomic / Animals / Biomedical and Life Sciences / Biomedicine / Cancer / Carcinoma, Neuroendocrine - diagnostic imaging / Carcinoma, Neuroendocrine - drug therapy / Carcinoma, Neuroendocrine - pathology / Care and treatment / Cell Differentiation - drug effects / Chemotherapy / Complications and side effects / Dacarbazine - administration & dosage / Dacarbazine - analogs & derivatives / Dacarbazine - therapeutic use / Diagnosis / Dosage and administration / Female / Humans / Immunotherapy / Medicine/Public Health / Metastasis / Middle Aged / Neoplasm Metastasis / Pancreatic cancer / Pancreatic Neoplasms - diagnostic imaging / Pancreatic Neoplasms - drug therapy / Pancreatic Neoplasms - pathology / Review / Temozolomide / Tomography, X-Ray Computed